nodes	percent_of_prediction	percent_of_DWPC	metapath
Acitretin—psoriasis—systemic scleroderma	0.754	1	CtDrD
Acitretin—ALB—Captopril—systemic scleroderma	0.031	0.366	CbGbCtD
Acitretin—ALB—Mycophenolate mofetil—systemic scleroderma	0.0244	0.288	CbGbCtD
Acitretin—ALB—Prednisone—systemic scleroderma	0.0195	0.23	CbGbCtD
Acitretin—ALB—Methotrexate—systemic scleroderma	0.00979	0.116	CbGbCtD
Acitretin—RBP1—smooth muscle tissue—systemic scleroderma	0.000951	0.0997	CbGeAlD
Acitretin—RBP1—skin of body—systemic scleroderma	0.000939	0.0984	CbGeAlD
Acitretin—RBP1—digestive system—systemic scleroderma	0.000751	0.0787	CbGeAlD
Acitretin—RARG—skin of body—systemic scleroderma	0.000709	0.0743	CbGeAlD
Acitretin—RARB—tendon—systemic scleroderma	0.000661	0.0693	CbGeAlD
Acitretin—RXRG—tendon—systemic scleroderma	0.000646	0.0678	CbGeAlD
Acitretin—RBP1—Retinoid metabolism and transport—HSPG2—systemic scleroderma	0.000634	0.112	CbGpPWpGaD
Acitretin—RBP1—lung—systemic scleroderma	0.000627	0.0657	CbGeAlD
Acitretin—RXRB—tendon—systemic scleroderma	0.000608	0.0637	CbGeAlD
Acitretin—RARB—lung—systemic scleroderma	0.00058	0.0608	CbGeAlD
Acitretin—RARG—digestive system—systemic scleroderma	0.000567	0.0594	CbGeAlD
Acitretin—RARG—tendon—systemic scleroderma	0.000539	0.0566	CbGeAlD
Acitretin—RXRB—lung—systemic scleroderma	0.000533	0.0559	CbGeAlD
Acitretin—RARA—tendon—systemic scleroderma	0.000507	0.0532	CbGeAlD
Acitretin—RARG—lung—systemic scleroderma	0.000473	0.0496	CbGeAlD
Acitretin—RARA—lung—systemic scleroderma	0.000445	0.0467	CbGeAlD
Acitretin—RBP1—Diseases associated with visual transduction—HSPG2—systemic scleroderma	0.000324	0.0574	CbGpPWpGaD
Acitretin—RXRG—a6b1 and a6b4 Integrin signaling—IL1A—systemic scleroderma	0.000196	0.0347	CbGpPWpGaD
Acitretin—RXRA—YAP1- and WWTR1 (TAZ)-stimulated gene expression—CTGF—systemic scleroderma	0.000192	0.034	CbGpPWpGaD
Acitretin—RXRB—a6b1 and a6b4 Integrin signaling—IL1A—systemic scleroderma	0.000184	0.0326	CbGpPWpGaD
Acitretin—RARB—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000172	0.0306	CbGpPWpGaD
Acitretin—RARA—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000165	0.0293	CbGpPWpGaD
Acitretin—RARG—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—systemic scleroderma	0.000134	0.0238	CbGpPWpGaD
Acitretin—RXRG—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—systemic scleroderma	0.000123	0.0218	CbGpPWpGaD
Acitretin—RARB—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—systemic scleroderma	0.000121	0.0214	CbGpPWpGaD
Acitretin—RXRB—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—systemic scleroderma	0.000116	0.0205	CbGpPWpGaD
Acitretin—RARA—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—systemic scleroderma	0.000116	0.0205	CbGpPWpGaD
Acitretin—ALB—Lipoprotein metabolism—HSPG2—systemic scleroderma	0.000112	0.0199	CbGpPWpGaD
Acitretin—RXRA—a6b1 and a6b4 Integrin signaling—IL1A—systemic scleroderma	9.59e-05	0.017	CbGpPWpGaD
Acitretin—ALB—Binding and Uptake of Ligands by Scavenger Receptors—COL1A2—systemic scleroderma	8.75e-05	0.0155	CbGpPWpGaD
Acitretin—RXRA—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	8.62e-05	0.0153	CbGpPWpGaD
Acitretin—RARG—Generic Transcription Pathway—SMAD7—systemic scleroderma	8.51e-05	0.0151	CbGpPWpGaD
Acitretin—Vomiting—Mometasone—systemic scleroderma	8.03e-05	0.000551	CcSEcCtD
Acitretin—Dry mouth—Lisinopril—systemic scleroderma	8.02e-05	0.00055	CcSEcCtD
Acitretin—Sweating increased—Prednisone—systemic scleroderma	8e-05	0.000549	CcSEcCtD
Acitretin—Feeling abnormal—Azathioprine—systemic scleroderma	7.98e-05	0.000548	CcSEcCtD
Acitretin—Rash—Mometasone—systemic scleroderma	7.97e-05	0.000547	CcSEcCtD
Acitretin—Asthenia—Captopril—systemic scleroderma	7.96e-05	0.000546	CcSEcCtD
Acitretin—Dermatitis—Mometasone—systemic scleroderma	7.96e-05	0.000546	CcSEcCtD
Acitretin—Decreased appetite—Leflunomide—systemic scleroderma	7.95e-05	0.000546	CcSEcCtD
Acitretin—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	7.95e-05	0.000545	CcSEcCtD
Acitretin—Osteoarthritis—Methotrexate—systemic scleroderma	7.94e-05	0.000545	CcSEcCtD
Acitretin—Gastrointestinal pain—Azathioprine—systemic scleroderma	7.92e-05	0.000543	CcSEcCtD
Acitretin—Headache—Mometasone—systemic scleroderma	7.92e-05	0.000543	CcSEcCtD
Acitretin—Gastrointestinal disorder—Leflunomide—systemic scleroderma	7.9e-05	0.000542	CcSEcCtD
Acitretin—Insomnia—Mycophenolic acid—systemic scleroderma	7.89e-05	0.000541	CcSEcCtD
Acitretin—Fatigue—Leflunomide—systemic scleroderma	7.89e-05	0.000541	CcSEcCtD
Acitretin—Oedema—Lisinopril—systemic scleroderma	7.86e-05	0.000539	CcSEcCtD
Acitretin—Pruritus—Captopril—systemic scleroderma	7.85e-05	0.000539	CcSEcCtD
Acitretin—Paraesthesia—Mycophenolic acid—systemic scleroderma	7.84e-05	0.000538	CcSEcCtD
Acitretin—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	7.83e-05	0.000537	CcSEcCtD
Acitretin—Constipation—Leflunomide—systemic scleroderma	7.82e-05	0.000537	CcSEcCtD
Acitretin—Pain—Leflunomide—systemic scleroderma	7.82e-05	0.000537	CcSEcCtD
Acitretin—Infection—Lisinopril—systemic scleroderma	7.81e-05	0.000536	CcSEcCtD
Acitretin—RXRG—Generic Transcription Pathway—SMAD7—systemic scleroderma	7.78e-05	0.0138	CbGpPWpGaD
Acitretin—Somnolence—Mycophenolic acid—systemic scleroderma	7.76e-05	0.000532	CcSEcCtD
Acitretin—Angioedema—Mycophenolate mofetil—systemic scleroderma	7.71e-05	0.000529	CcSEcCtD
Acitretin—Dyspepsia—Mycophenolic acid—systemic scleroderma	7.68e-05	0.000527	CcSEcCtD
Acitretin—Body temperature increased—Azathioprine—systemic scleroderma	7.66e-05	0.000525	CcSEcCtD
Acitretin—Abdominal pain—Azathioprine—systemic scleroderma	7.66e-05	0.000525	CcSEcCtD
Acitretin—Skin disorder—Lisinopril—systemic scleroderma	7.63e-05	0.000524	CcSEcCtD
Acitretin—RARB—Generic Transcription Pathway—SMAD7—systemic scleroderma	7.63e-05	0.0135	CbGpPWpGaD
Acitretin—Malaise—Mycophenolate mofetil—systemic scleroderma	7.61e-05	0.000522	CcSEcCtD
Acitretin—Hyperhidrosis—Lisinopril—systemic scleroderma	7.6e-05	0.000521	CcSEcCtD
Acitretin—Diarrhoea—Captopril—systemic scleroderma	7.59e-05	0.000521	CcSEcCtD
Acitretin—Decreased appetite—Mycophenolic acid—systemic scleroderma	7.59e-05	0.00052	CcSEcCtD
Acitretin—Erectile dysfunction—Prednisone—systemic scleroderma	7.56e-05	0.000519	CcSEcCtD
Acitretin—Feeling abnormal—Leflunomide—systemic scleroderma	7.54e-05	0.000517	CcSEcCtD
Acitretin—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	7.53e-05	0.000517	CcSEcCtD
Acitretin—Fatigue—Mycophenolic acid—systemic scleroderma	7.52e-05	0.000516	CcSEcCtD
Acitretin—Nausea—Mometasone—systemic scleroderma	7.51e-05	0.000515	CcSEcCtD
Acitretin—Anorexia—Lisinopril—systemic scleroderma	7.49e-05	0.000514	CcSEcCtD
Acitretin—Gastrointestinal pain—Leflunomide—systemic scleroderma	7.48e-05	0.000513	CcSEcCtD
Acitretin—Weight increased—Prednisone—systemic scleroderma	7.47e-05	0.000513	CcSEcCtD
Acitretin—ALB—Lipid and lipoprotein metabolism—HSPG2—systemic scleroderma	7.47e-05	0.0132	CbGpPWpGaD
Acitretin—Pain—Mycophenolic acid—systemic scleroderma	7.46e-05	0.000512	CcSEcCtD
Acitretin—Constipation—Mycophenolic acid—systemic scleroderma	7.46e-05	0.000512	CcSEcCtD
Acitretin—Weight decreased—Prednisone—systemic scleroderma	7.43e-05	0.00051	CcSEcCtD
Acitretin—Cough—Mycophenolate mofetil—systemic scleroderma	7.36e-05	0.000505	CcSEcCtD
Acitretin—Dizziness—Captopril—systemic scleroderma	7.34e-05	0.000504	CcSEcCtD
Acitretin—Liver function test abnormal—Methotrexate—systemic scleroderma	7.33e-05	0.000503	CcSEcCtD
Acitretin—RARA—Generic Transcription Pathway—SMAD7—systemic scleroderma	7.32e-05	0.013	CbGpPWpGaD
Acitretin—RXRB—Generic Transcription Pathway—SMAD7—systemic scleroderma	7.32e-05	0.013	CbGpPWpGaD
Acitretin—Depression—Prednisone—systemic scleroderma	7.3e-05	0.000501	CcSEcCtD
Acitretin—Urticaria—Leflunomide—systemic scleroderma	7.27e-05	0.000499	CcSEcCtD
Acitretin—Abdominal pain—Leflunomide—systemic scleroderma	7.23e-05	0.000496	CcSEcCtD
Acitretin—Body temperature increased—Leflunomide—systemic scleroderma	7.23e-05	0.000496	CcSEcCtD
Acitretin—Feeling abnormal—Mycophenolic acid—systemic scleroderma	7.19e-05	0.000493	CcSEcCtD
Acitretin—Arthralgia—Mycophenolate mofetil—systemic scleroderma	7.18e-05	0.000493	CcSEcCtD
Acitretin—Chest pain—Mycophenolate mofetil—systemic scleroderma	7.18e-05	0.000493	CcSEcCtD
Acitretin—Myalgia—Mycophenolate mofetil—systemic scleroderma	7.18e-05	0.000493	CcSEcCtD
Acitretin—Neuropathy peripheral—Prednisone—systemic scleroderma	7.17e-05	0.000492	CcSEcCtD
Acitretin—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	7.16e-05	0.000491	CcSEcCtD
Acitretin—Anxiety—Mycophenolate mofetil—systemic scleroderma	7.16e-05	0.000491	CcSEcCtD
Acitretin—Hypersensitivity—Azathioprine—systemic scleroderma	7.14e-05	0.00049	CcSEcCtD
Acitretin—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	7.14e-05	0.00049	CcSEcCtD
Acitretin—Insomnia—Lisinopril—systemic scleroderma	7.11e-05	0.000488	CcSEcCtD
Acitretin—Discomfort—Mycophenolate mofetil—systemic scleroderma	7.1e-05	0.000487	CcSEcCtD
Acitretin—Paraesthesia—Lisinopril—systemic scleroderma	7.06e-05	0.000484	CcSEcCtD
Acitretin—Vomiting—Captopril—systemic scleroderma	7.06e-05	0.000484	CcSEcCtD
Acitretin—Dry mouth—Mycophenolate mofetil—systemic scleroderma	7.03e-05	0.000482	CcSEcCtD
Acitretin—Rash—Captopril—systemic scleroderma	7e-05	0.00048	CcSEcCtD
Acitretin—Dermatitis—Captopril—systemic scleroderma	6.99e-05	0.00048	CcSEcCtD
Acitretin—Somnolence—Lisinopril—systemic scleroderma	6.99e-05	0.000479	CcSEcCtD
Acitretin—Headache—Captopril—systemic scleroderma	6.95e-05	0.000477	CcSEcCtD
Acitretin—Dyspepsia—Lisinopril—systemic scleroderma	6.92e-05	0.000475	CcSEcCtD
Acitretin—Body temperature increased—Mycophenolic acid—systemic scleroderma	6.9e-05	0.000473	CcSEcCtD
Acitretin—Abdominal pain—Mycophenolic acid—systemic scleroderma	6.9e-05	0.000473	CcSEcCtD
Acitretin—Oedema—Mycophenolate mofetil—systemic scleroderma	6.89e-05	0.000472	CcSEcCtD
Acitretin—Infection—Mycophenolate mofetil—systemic scleroderma	6.84e-05	0.000469	CcSEcCtD
Acitretin—Decreased appetite—Lisinopril—systemic scleroderma	6.83e-05	0.000469	CcSEcCtD
Acitretin—Gastrointestinal disorder—Lisinopril—systemic scleroderma	6.79e-05	0.000466	CcSEcCtD
Acitretin—Fatigue—Lisinopril—systemic scleroderma	6.78e-05	0.000465	CcSEcCtD
Acitretin—Hypersensitivity—Leflunomide—systemic scleroderma	6.74e-05	0.000462	CcSEcCtD
Acitretin—Pancreatitis—Methotrexate—systemic scleroderma	6.73e-05	0.000461	CcSEcCtD
Acitretin—Constipation—Lisinopril—systemic scleroderma	6.72e-05	0.000461	CcSEcCtD
Acitretin—Pain—Lisinopril—systemic scleroderma	6.72e-05	0.000461	CcSEcCtD
Acitretin—Skin disorder—Mycophenolate mofetil—systemic scleroderma	6.69e-05	0.000459	CcSEcCtD
Acitretin—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	6.66e-05	0.000457	CcSEcCtD
Acitretin—Diarrhoea—Azathioprine—systemic scleroderma	6.63e-05	0.000455	CcSEcCtD
Acitretin—Haemoglobin—Prednisone—systemic scleroderma	6.6e-05	0.000453	CcSEcCtD
Acitretin—RXRA—PPARA activates gene expression—CTGF—systemic scleroderma	6.6e-05	0.0117	CbGpPWpGaD
Acitretin—Nausea—Captopril—systemic scleroderma	6.59e-05	0.000452	CcSEcCtD
Acitretin—Haemorrhage—Prednisone—systemic scleroderma	6.57e-05	0.000451	CcSEcCtD
Acitretin—Anorexia—Mycophenolate mofetil—systemic scleroderma	6.56e-05	0.00045	CcSEcCtD
Acitretin—Asthenia—Leflunomide—systemic scleroderma	6.56e-05	0.00045	CcSEcCtD
Acitretin—ALB—Folate Metabolism—CSF1—systemic scleroderma	6.55e-05	0.0116	CbGpPWpGaD
Acitretin—Pancytopenia—Methotrexate—systemic scleroderma	6.52e-05	0.000447	CcSEcCtD
Acitretin—Feeling abnormal—Lisinopril—systemic scleroderma	6.48e-05	0.000444	CcSEcCtD
Acitretin—Pruritus—Leflunomide—systemic scleroderma	6.47e-05	0.000444	CcSEcCtD
Acitretin—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CTGF—systemic scleroderma	6.46e-05	0.0115	CbGpPWpGaD
Acitretin—Gastrointestinal pain—Lisinopril—systemic scleroderma	6.43e-05	0.000441	CcSEcCtD
Acitretin—Dysuria—Methotrexate—systemic scleroderma	6.42e-05	0.00044	CcSEcCtD
Acitretin—Dizziness—Azathioprine—systemic scleroderma	6.41e-05	0.000439	CcSEcCtD
Acitretin—Erectile dysfunction—Methotrexate—systemic scleroderma	6.32e-05	0.000433	CcSEcCtD
Acitretin—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	6.27e-05	0.00043	CcSEcCtD
Acitretin—Photosensitivity reaction—Methotrexate—systemic scleroderma	6.26e-05	0.00043	CcSEcCtD
Acitretin—Asthenia—Mycophenolic acid—systemic scleroderma	6.26e-05	0.00043	CcSEcCtD
Acitretin—Diarrhoea—Leflunomide—systemic scleroderma	6.26e-05	0.000429	CcSEcCtD
Acitretin—Urticaria—Lisinopril—systemic scleroderma	6.24e-05	0.000428	CcSEcCtD
Acitretin—Insomnia—Mycophenolate mofetil—systemic scleroderma	6.23e-05	0.000427	CcSEcCtD
Acitretin—Body temperature increased—Lisinopril—systemic scleroderma	6.21e-05	0.000426	CcSEcCtD
Acitretin—Abdominal pain—Lisinopril—systemic scleroderma	6.21e-05	0.000426	CcSEcCtD
Acitretin—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	6.18e-05	0.000424	CcSEcCtD
Acitretin—Pruritus—Mycophenolic acid—systemic scleroderma	6.17e-05	0.000424	CcSEcCtD
Acitretin—Vomiting—Azathioprine—systemic scleroderma	6.16e-05	0.000423	CcSEcCtD
Acitretin—Eye disorder—Prednisone—systemic scleroderma	6.14e-05	0.000421	CcSEcCtD
Acitretin—Somnolence—Mycophenolate mofetil—systemic scleroderma	6.12e-05	0.00042	CcSEcCtD
Acitretin—Rash—Azathioprine—systemic scleroderma	6.11e-05	0.000419	CcSEcCtD
Acitretin—Dermatitis—Azathioprine—systemic scleroderma	6.1e-05	0.000419	CcSEcCtD
Acitretin—Depression—Methotrexate—systemic scleroderma	6.1e-05	0.000418	CcSEcCtD
Acitretin—Flushing—Prednisone—systemic scleroderma	6.1e-05	0.000418	CcSEcCtD
Acitretin—Headache—Azathioprine—systemic scleroderma	6.07e-05	0.000416	CcSEcCtD
Acitretin—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	6.06e-05	0.000416	CcSEcCtD
Acitretin—Dizziness—Leflunomide—systemic scleroderma	6.05e-05	0.000415	CcSEcCtD
Acitretin—RXRA—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—systemic scleroderma	6.02e-05	0.0107	CbGpPWpGaD
Acitretin—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	5.99e-05	0.000411	CcSEcCtD
Acitretin—Diarrhoea—Mycophenolic acid—systemic scleroderma	5.97e-05	0.00041	CcSEcCtD
Acitretin—Stomatitis—Methotrexate—systemic scleroderma	5.96e-05	0.000409	CcSEcCtD
Acitretin—Angiopathy—Prednisone—systemic scleroderma	5.96e-05	0.000409	CcSEcCtD
Acitretin—Conjunctivitis—Methotrexate—systemic scleroderma	5.95e-05	0.000408	CcSEcCtD
Acitretin—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	5.95e-05	0.000408	CcSEcCtD
Acitretin—Immune system disorder—Prednisone—systemic scleroderma	5.93e-05	0.000407	CcSEcCtD
Acitretin—Pain—Mycophenolate mofetil—systemic scleroderma	5.89e-05	0.000404	CcSEcCtD
Acitretin—Constipation—Mycophenolate mofetil—systemic scleroderma	5.89e-05	0.000404	CcSEcCtD
Acitretin—Haematuria—Methotrexate—systemic scleroderma	5.83e-05	0.0004	CcSEcCtD
Acitretin—ALB—Platelet degranulation—SELP—systemic scleroderma	5.82e-05	0.0103	CbGpPWpGaD
Acitretin—Vomiting—Leflunomide—systemic scleroderma	5.82e-05	0.000399	CcSEcCtD
Acitretin—Alopecia—Prednisone—systemic scleroderma	5.81e-05	0.000398	CcSEcCtD
Acitretin—Hypersensitivity—Lisinopril—systemic scleroderma	5.79e-05	0.000397	CcSEcCtD
Acitretin—Dizziness—Mycophenolic acid—systemic scleroderma	5.77e-05	0.000396	CcSEcCtD
Acitretin—Epistaxis—Methotrexate—systemic scleroderma	5.77e-05	0.000396	CcSEcCtD
Acitretin—Rash—Leflunomide—systemic scleroderma	5.77e-05	0.000396	CcSEcCtD
Acitretin—Dermatitis—Leflunomide—systemic scleroderma	5.76e-05	0.000395	CcSEcCtD
Acitretin—Nausea—Azathioprine—systemic scleroderma	5.75e-05	0.000395	CcSEcCtD
Acitretin—Headache—Leflunomide—systemic scleroderma	5.73e-05	0.000393	CcSEcCtD
Acitretin—Erythema—Prednisone—systemic scleroderma	5.72e-05	0.000392	CcSEcCtD
Acitretin—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	5.68e-05	0.000389	CcSEcCtD
Acitretin—Asthenia—Lisinopril—systemic scleroderma	5.64e-05	0.000387	CcSEcCtD
Acitretin—RBP1—Disease—SMAD7—systemic scleroderma	5.63e-05	0.00999	CbGpPWpGaD
Acitretin—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	5.63e-05	0.000386	CcSEcCtD
Acitretin—Pruritus—Lisinopril—systemic scleroderma	5.56e-05	0.000381	CcSEcCtD
Acitretin—Vomiting—Mycophenolic acid—systemic scleroderma	5.55e-05	0.000381	CcSEcCtD
Acitretin—ALB—Response to elevated platelet cytosolic Ca2+—SELP—systemic scleroderma	5.55e-05	0.00984	CbGpPWpGaD
Acitretin—Haemoglobin—Methotrexate—systemic scleroderma	5.52e-05	0.000379	CcSEcCtD
Acitretin—Rash—Mycophenolic acid—systemic scleroderma	5.5e-05	0.000377	CcSEcCtD
Acitretin—Dermatitis—Mycophenolic acid—systemic scleroderma	5.5e-05	0.000377	CcSEcCtD
Acitretin—Haemorrhage—Methotrexate—systemic scleroderma	5.49e-05	0.000377	CcSEcCtD
Acitretin—Hepatitis—Methotrexate—systemic scleroderma	5.49e-05	0.000377	CcSEcCtD
Acitretin—Urticaria—Mycophenolate mofetil—systemic scleroderma	5.47e-05	0.000375	CcSEcCtD
Acitretin—Headache—Mycophenolic acid—systemic scleroderma	5.47e-05	0.000375	CcSEcCtD
Acitretin—Pharyngitis—Methotrexate—systemic scleroderma	5.45e-05	0.000374	CcSEcCtD
Acitretin—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	5.44e-05	0.000373	CcSEcCtD
Acitretin—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	5.44e-05	0.000373	CcSEcCtD
Acitretin—Nausea—Leflunomide—systemic scleroderma	5.43e-05	0.000373	CcSEcCtD
Acitretin—Vision blurred—Prednisone—systemic scleroderma	5.39e-05	0.00037	CcSEcCtD
Acitretin—Diarrhoea—Lisinopril—systemic scleroderma	5.38e-05	0.000369	CcSEcCtD
Acitretin—Ill-defined disorder—Prednisone—systemic scleroderma	5.31e-05	0.000364	CcSEcCtD
Acitretin—Visual impairment—Methotrexate—systemic scleroderma	5.29e-05	0.000363	CcSEcCtD
Acitretin—Angioedema—Prednisone—systemic scleroderma	5.23e-05	0.000359	CcSEcCtD
Acitretin—Dizziness—Lisinopril—systemic scleroderma	5.2e-05	0.000357	CcSEcCtD
Acitretin—Nausea—Mycophenolic acid—systemic scleroderma	5.18e-05	0.000356	CcSEcCtD
Acitretin—Malaise—Prednisone—systemic scleroderma	5.16e-05	0.000354	CcSEcCtD
Acitretin—RBP1—Disease—TGFBI—systemic scleroderma	5.15e-05	0.00914	CbGpPWpGaD
Acitretin—Eye disorder—Methotrexate—systemic scleroderma	5.13e-05	0.000352	CcSEcCtD
Acitretin—Tinnitus—Methotrexate—systemic scleroderma	5.12e-05	0.000351	CcSEcCtD
Acitretin—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	5.07e-05	0.000348	CcSEcCtD
Acitretin—Vomiting—Lisinopril—systemic scleroderma	5e-05	0.000343	CcSEcCtD
Acitretin—Angiopathy—Methotrexate—systemic scleroderma	4.98e-05	0.000342	CcSEcCtD
Acitretin—Immune system disorder—Methotrexate—systemic scleroderma	4.96e-05	0.00034	CcSEcCtD
Acitretin—Rash—Lisinopril—systemic scleroderma	4.96e-05	0.00034	CcSEcCtD
Acitretin—Dermatitis—Lisinopril—systemic scleroderma	4.95e-05	0.00034	CcSEcCtD
Acitretin—Asthenia—Mycophenolate mofetil—systemic scleroderma	4.94e-05	0.000339	CcSEcCtD
Acitretin—Chills—Methotrexate—systemic scleroderma	4.93e-05	0.000338	CcSEcCtD
Acitretin—Headache—Lisinopril—systemic scleroderma	4.92e-05	0.000338	CcSEcCtD
Acitretin—Pruritus—Mycophenolate mofetil—systemic scleroderma	4.87e-05	0.000334	CcSEcCtD
Acitretin—Arthralgia—Prednisone—systemic scleroderma	4.87e-05	0.000334	CcSEcCtD
Acitretin—Myalgia—Prednisone—systemic scleroderma	4.87e-05	0.000334	CcSEcCtD
Acitretin—Anxiety—Prednisone—systemic scleroderma	4.85e-05	0.000333	CcSEcCtD
Acitretin—Alopecia—Methotrexate—systemic scleroderma	4.85e-05	0.000333	CcSEcCtD
Acitretin—Discomfort—Prednisone—systemic scleroderma	4.81e-05	0.00033	CcSEcCtD
Acitretin—Erythema—Methotrexate—systemic scleroderma	4.78e-05	0.000328	CcSEcCtD
Acitretin—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	4.71e-05	0.000323	CcSEcCtD
Acitretin—RARG—Generic Transcription Pathway—CTGF—systemic scleroderma	4.71e-05	0.00834	CbGpPWpGaD
Acitretin—Dysgeusia—Methotrexate—systemic scleroderma	4.68e-05	0.000321	CcSEcCtD
Acitretin—Nausea—Lisinopril—systemic scleroderma	4.67e-05	0.00032	CcSEcCtD
Acitretin—Oedema—Prednisone—systemic scleroderma	4.67e-05	0.00032	CcSEcCtD
Acitretin—Infection—Prednisone—systemic scleroderma	4.64e-05	0.000318	CcSEcCtD
Acitretin—Back pain—Methotrexate—systemic scleroderma	4.62e-05	0.000317	CcSEcCtD
Acitretin—Dizziness—Mycophenolate mofetil—systemic scleroderma	4.55e-05	0.000312	CcSEcCtD
Acitretin—Skin disorder—Prednisone—systemic scleroderma	4.53e-05	0.000311	CcSEcCtD
Acitretin—Hyperhidrosis—Prednisone—systemic scleroderma	4.51e-05	0.00031	CcSEcCtD
Acitretin—Vision blurred—Methotrexate—systemic scleroderma	4.51e-05	0.000309	CcSEcCtD
Acitretin—CYP26A1—Adipogenesis—TGFB1—systemic scleroderma	4.48e-05	0.00794	CbGpPWpGaD
Acitretin—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—CTGF—systemic scleroderma	4.45e-05	0.00789	CbGpPWpGaD
Acitretin—Anorexia—Prednisone—systemic scleroderma	4.45e-05	0.000305	CcSEcCtD
Acitretin—Ill-defined disorder—Methotrexate—systemic scleroderma	4.44e-05	0.000304	CcSEcCtD
Acitretin—Vomiting—Mycophenolate mofetil—systemic scleroderma	4.38e-05	0.0003	CcSEcCtD
Acitretin—Rash—Mycophenolate mofetil—systemic scleroderma	4.34e-05	0.000298	CcSEcCtD
Acitretin—Dermatitis—Mycophenolate mofetil—systemic scleroderma	4.34e-05	0.000298	CcSEcCtD
Acitretin—Headache—Mycophenolate mofetil—systemic scleroderma	4.31e-05	0.000296	CcSEcCtD
Acitretin—Malaise—Methotrexate—systemic scleroderma	4.31e-05	0.000296	CcSEcCtD
Acitretin—RXRG—Generic Transcription Pathway—CTGF—systemic scleroderma	4.3e-05	0.00763	CbGpPWpGaD
Acitretin—Musculoskeletal discomfort—Prednisone—systemic scleroderma	4.25e-05	0.000292	CcSEcCtD
Acitretin—Insomnia—Prednisone—systemic scleroderma	4.22e-05	0.00029	CcSEcCtD
Acitretin—RARB—Generic Transcription Pathway—CTGF—systemic scleroderma	4.22e-05	0.00748	CbGpPWpGaD
Acitretin—Paraesthesia—Prednisone—systemic scleroderma	4.19e-05	0.000288	CcSEcCtD
Acitretin—Cough—Methotrexate—systemic scleroderma	4.17e-05	0.000286	CcSEcCtD
Acitretin—RBP1—Disease—HSPG2—systemic scleroderma	4.11e-05	0.00729	CbGpPWpGaD
Acitretin—Dyspepsia—Prednisone—systemic scleroderma	4.11e-05	0.000282	CcSEcCtD
Acitretin—RARG—Gene Expression—SMAD7—systemic scleroderma	4.1e-05	0.00727	CbGpPWpGaD
Acitretin—Nausea—Mycophenolate mofetil—systemic scleroderma	4.09e-05	0.000281	CcSEcCtD
Acitretin—Arthralgia—Methotrexate—systemic scleroderma	4.07e-05	0.000279	CcSEcCtD
Acitretin—Myalgia—Methotrexate—systemic scleroderma	4.07e-05	0.000279	CcSEcCtD
Acitretin—Chest pain—Methotrexate—systemic scleroderma	4.07e-05	0.000279	CcSEcCtD
Acitretin—Decreased appetite—Prednisone—systemic scleroderma	4.06e-05	0.000278	CcSEcCtD
Acitretin—RARA—Generic Transcription Pathway—CTGF—systemic scleroderma	4.05e-05	0.00718	CbGpPWpGaD
Acitretin—RXRB—Generic Transcription Pathway—CTGF—systemic scleroderma	4.05e-05	0.00718	CbGpPWpGaD
Acitretin—Fatigue—Prednisone—systemic scleroderma	4.02e-05	0.000276	CcSEcCtD
Acitretin—Discomfort—Methotrexate—systemic scleroderma	4.02e-05	0.000276	CcSEcCtD
Acitretin—Constipation—Prednisone—systemic scleroderma	3.99e-05	0.000274	CcSEcCtD
Acitretin—RBP1—Disease—CSK—systemic scleroderma	3.97e-05	0.00704	CbGpPWpGaD
Acitretin—RBP1—Signaling Pathways—SMAD7—systemic scleroderma	3.94e-05	0.00699	CbGpPWpGaD
Acitretin—Infection—Methotrexate—systemic scleroderma	3.88e-05	0.000266	CcSEcCtD
Acitretin—Feeling abnormal—Prednisone—systemic scleroderma	3.85e-05	0.000264	CcSEcCtD
Acitretin—Gastrointestinal pain—Prednisone—systemic scleroderma	3.82e-05	0.000262	CcSEcCtD
Acitretin—RXRA—Generic Transcription Pathway—SMAD7—systemic scleroderma	3.81e-05	0.00676	CbGpPWpGaD
Acitretin—RARG—Gene Expression—TNFSF13—systemic scleroderma	3.81e-05	0.00676	CbGpPWpGaD
Acitretin—Skin disorder—Methotrexate—systemic scleroderma	3.79e-05	0.00026	CcSEcCtD
Acitretin—Hyperhidrosis—Methotrexate—systemic scleroderma	3.77e-05	0.000259	CcSEcCtD
Acitretin—RXRG—Gene Expression—SMAD7—systemic scleroderma	3.75e-05	0.00665	CbGpPWpGaD
Acitretin—RBP1—Disease—CD247—systemic scleroderma	3.73e-05	0.00662	CbGpPWpGaD
Acitretin—Anorexia—Methotrexate—systemic scleroderma	3.72e-05	0.000255	CcSEcCtD
Acitretin—Urticaria—Prednisone—systemic scleroderma	3.71e-05	0.000254	CcSEcCtD
Acitretin—Abdominal pain—Prednisone—systemic scleroderma	3.69e-05	0.000253	CcSEcCtD
Acitretin—Body temperature increased—Prednisone—systemic scleroderma	3.69e-05	0.000253	CcSEcCtD
Acitretin—RARB—Gene Expression—SMAD7—systemic scleroderma	3.68e-05	0.00652	CbGpPWpGaD
Acitretin—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	3.55e-05	0.000244	CcSEcCtD
Acitretin—Insomnia—Methotrexate—systemic scleroderma	3.53e-05	0.000242	CcSEcCtD
Acitretin—RARA—Gene Expression—SMAD7—systemic scleroderma	3.52e-05	0.00625	CbGpPWpGaD
Acitretin—RXRB—Gene Expression—SMAD7—systemic scleroderma	3.52e-05	0.00625	CbGpPWpGaD
Acitretin—Paraesthesia—Methotrexate—systemic scleroderma	3.5e-05	0.00024	CcSEcCtD
Acitretin—RXRG—Gene Expression—TNFSF13—systemic scleroderma	3.48e-05	0.00618	CbGpPWpGaD
Acitretin—Somnolence—Methotrexate—systemic scleroderma	3.47e-05	0.000238	CcSEcCtD
Acitretin—Hypersensitivity—Prednisone—systemic scleroderma	3.44e-05	0.000236	CcSEcCtD
Acitretin—Dyspepsia—Methotrexate—systemic scleroderma	3.43e-05	0.000236	CcSEcCtD
Acitretin—RARB—Gene Expression—TNFSF13—systemic scleroderma	3.42e-05	0.00606	CbGpPWpGaD
Acitretin—RXRG—Adipogenesis—TGFB1—systemic scleroderma	3.39e-05	0.00602	CbGpPWpGaD
Acitretin—Decreased appetite—Methotrexate—systemic scleroderma	3.39e-05	0.000233	CcSEcCtD
Acitretin—Gastrointestinal disorder—Methotrexate—systemic scleroderma	3.37e-05	0.000231	CcSEcCtD
Acitretin—Fatigue—Methotrexate—systemic scleroderma	3.36e-05	0.000231	CcSEcCtD
Acitretin—Asthenia—Prednisone—systemic scleroderma	3.35e-05	0.00023	CcSEcCtD
Acitretin—Pain—Methotrexate—systemic scleroderma	3.34e-05	0.000229	CcSEcCtD
Acitretin—Pruritus—Prednisone—systemic scleroderma	3.3e-05	0.000227	CcSEcCtD
Acitretin—RARA—Gene Expression—TNFSF13—systemic scleroderma	3.28e-05	0.00581	CbGpPWpGaD
Acitretin—RXRB—Gene Expression—TNFSF13—systemic scleroderma	3.28e-05	0.00581	CbGpPWpGaD
Acitretin—Feeling abnormal—Methotrexate—systemic scleroderma	3.21e-05	0.000221	CcSEcCtD
Acitretin—Diarrhoea—Prednisone—systemic scleroderma	3.19e-05	0.000219	CcSEcCtD
Acitretin—Gastrointestinal pain—Methotrexate—systemic scleroderma	3.19e-05	0.000219	CcSEcCtD
Acitretin—RARA—Adipogenesis—TGFB1—systemic scleroderma	3.19e-05	0.00566	CbGpPWpGaD
Acitretin—Urticaria—Methotrexate—systemic scleroderma	3.1e-05	0.000213	CcSEcCtD
Acitretin—Dizziness—Prednisone—systemic scleroderma	3.09e-05	0.000212	CcSEcCtD
Acitretin—Body temperature increased—Methotrexate—systemic scleroderma	3.08e-05	0.000212	CcSEcCtD
Acitretin—Abdominal pain—Methotrexate—systemic scleroderma	3.08e-05	0.000212	CcSEcCtD
Acitretin—RBP1—Signaling Pathways—RHOB—systemic scleroderma	3.05e-05	0.00541	CbGpPWpGaD
Acitretin—Vomiting—Prednisone—systemic scleroderma	2.97e-05	0.000204	CcSEcCtD
Acitretin—Rash—Prednisone—systemic scleroderma	2.94e-05	0.000202	CcSEcCtD
Acitretin—Dermatitis—Prednisone—systemic scleroderma	2.94e-05	0.000202	CcSEcCtD
Acitretin—Headache—Prednisone—systemic scleroderma	2.92e-05	0.000201	CcSEcCtD
Acitretin—RBP1—Signaling Pathways—HSPG2—systemic scleroderma	2.88e-05	0.0051	CbGpPWpGaD
Acitretin—Hypersensitivity—Methotrexate—systemic scleroderma	2.87e-05	0.000197	CcSEcCtD
Acitretin—CYP26A1—Metabolism—HSPG2—systemic scleroderma	2.81e-05	0.00497	CbGpPWpGaD
Acitretin—Asthenia—Methotrexate—systemic scleroderma	2.8e-05	0.000192	CcSEcCtD
Acitretin—RBP1—Signaling Pathways—CSK—systemic scleroderma	2.78e-05	0.00493	CbGpPWpGaD
Acitretin—RXRA—Developmental Biology—RHOB—systemic scleroderma	2.78e-05	0.00493	CbGpPWpGaD
Acitretin—Nausea—Prednisone—systemic scleroderma	2.77e-05	0.00019	CcSEcCtD
Acitretin—Pruritus—Methotrexate—systemic scleroderma	2.76e-05	0.000189	CcSEcCtD
Acitretin—ALB—Vitamin B12 Metabolism—CCL2—systemic scleroderma	2.72e-05	0.00482	CbGpPWpGaD
Acitretin—Diarrhoea—Methotrexate—systemic scleroderma	2.67e-05	0.000183	CcSEcCtD
Acitretin—ALB—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	2.58e-05	0.00458	CbGpPWpGaD
Acitretin—Dizziness—Methotrexate—systemic scleroderma	2.58e-05	0.000177	CcSEcCtD
Acitretin—RXRA—Transcriptional regulation of white adipocyte differentiation—TGFB1—systemic scleroderma	2.53e-05	0.00448	CbGpPWpGaD
Acitretin—Vomiting—Methotrexate—systemic scleroderma	2.48e-05	0.00017	CcSEcCtD
Acitretin—Rash—Methotrexate—systemic scleroderma	2.46e-05	0.000169	CcSEcCtD
Acitretin—Dermatitis—Methotrexate—systemic scleroderma	2.46e-05	0.000169	CcSEcCtD
Acitretin—RARB—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	2.45e-05	0.00434	CbGpPWpGaD
Acitretin—Headache—Methotrexate—systemic scleroderma	2.44e-05	0.000168	CcSEcCtD
Acitretin—ALB—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	2.41e-05	0.00428	CbGpPWpGaD
Acitretin—RARA—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	2.34e-05	0.00416	CbGpPWpGaD
Acitretin—RXRA—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.34e-05	0.00415	CbGpPWpGaD
Acitretin—Nausea—Methotrexate—systemic scleroderma	2.32e-05	0.000159	CcSEcCtD
Acitretin—RARG—Gene Expression—CTGF—systemic scleroderma	2.27e-05	0.00402	CbGpPWpGaD
Acitretin—ALB—Folate Metabolism—CCL2—systemic scleroderma	2.21e-05	0.00392	CbGpPWpGaD
Acitretin—ALB—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	2.2e-05	0.00389	CbGpPWpGaD
Acitretin—CYP26A1—Metabolism—CTGF—systemic scleroderma	2.13e-05	0.00377	CbGpPWpGaD
Acitretin—RXRA—Generic Transcription Pathway—CTGF—systemic scleroderma	2.11e-05	0.00374	CbGpPWpGaD
Acitretin—RXRG—Gene Expression—CTGF—systemic scleroderma	2.07e-05	0.00367	CbGpPWpGaD
Acitretin—ALB—Vitamin B12 Metabolism—IL1B—systemic scleroderma	2.06e-05	0.00366	CbGpPWpGaD
Acitretin—RARB—Gene Expression—CTGF—systemic scleroderma	2.03e-05	0.0036	CbGpPWpGaD
Acitretin—RXRB—Gene Expression—CTGF—systemic scleroderma	1.95e-05	0.00345	CbGpPWpGaD
Acitretin—RARA—Gene Expression—CTGF—systemic scleroderma	1.95e-05	0.00345	CbGpPWpGaD
Acitretin—RXRA—Gene Expression—SMAD7—systemic scleroderma	1.84e-05	0.00326	CbGpPWpGaD
Acitretin—RXRA—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.77e-05	0.00314	CbGpPWpGaD
Acitretin—ALB—Selenium Micronutrient Network—CCL2—systemic scleroderma	1.76e-05	0.00312	CbGpPWpGaD
Acitretin—RXRA—Gene Expression—TNFSF13—systemic scleroderma	1.71e-05	0.00303	CbGpPWpGaD
Acitretin—ALB—Folate Metabolism—IL1B—systemic scleroderma	1.68e-05	0.00298	CbGpPWpGaD
Acitretin—RXRA—Adipogenesis—TGFB1—systemic scleroderma	1.66e-05	0.00295	CbGpPWpGaD
Acitretin—RBP1—Signaling Pathways—EDN1—systemic scleroderma	1.56e-05	0.00276	CbGpPWpGaD
Acitretin—RXRA—NRF2 pathway—TGFB1—systemic scleroderma	1.51e-05	0.00269	CbGpPWpGaD
Acitretin—RBP1—Disease—NOS3—systemic scleroderma	1.36e-05	0.0024	CbGpPWpGaD
Acitretin—ALB—Selenium Micronutrient Network—IL1B—systemic scleroderma	1.33e-05	0.00236	CbGpPWpGaD
Acitretin—ALB—Hemostasis—SELP—systemic scleroderma	1.33e-05	0.00236	CbGpPWpGaD
Acitretin—ALB—Hemostasis—RHOB—systemic scleroderma	1.24e-05	0.0022	CbGpPWpGaD
Acitretin—RXRA—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	1.22e-05	0.00217	CbGpPWpGaD
Acitretin—ALB—Hemostasis—CSK—systemic scleroderma	1.13e-05	0.00201	CbGpPWpGaD
Acitretin—ALB—Platelet degranulation—TGFB1—systemic scleroderma	1.12e-05	0.00198	CbGpPWpGaD
Acitretin—ALB—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.07e-05	0.00189	CbGpPWpGaD
Acitretin—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	1.07e-05	0.00189	CbGpPWpGaD
Acitretin—RBP1—Signaling Pathways—CCL2—systemic scleroderma	1.07e-05	0.00189	CbGpPWpGaD
Acitretin—ALB—Hemostasis—ITGAM—systemic scleroderma	1.06e-05	0.00189	CbGpPWpGaD
Acitretin—RXRA—Metabolism—HSPG2—systemic scleroderma	1.04e-05	0.00185	CbGpPWpGaD
Acitretin—RXRA—Gene Expression—CTGF—systemic scleroderma	1.02e-05	0.0018	CbGpPWpGaD
Acitretin—RBP1—Signaling Pathways—NOS3—systemic scleroderma	9.49e-06	0.00168	CbGpPWpGaD
Acitretin—CYP26A1—Metabolism—NOS3—systemic scleroderma	9.25e-06	0.00164	CbGpPWpGaD
Acitretin—RXRA—Developmental Biology—MMP2—systemic scleroderma	9.22e-06	0.00164	CbGpPWpGaD
Acitretin—RBP1—Disease—TGFB1—systemic scleroderma	8.96e-06	0.00159	CbGpPWpGaD
Acitretin—ALB—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	8.09e-06	0.00143	CbGpPWpGaD
Acitretin—RXRA—Metabolism—CTGF—systemic scleroderma	7.9e-06	0.0014	CbGpPWpGaD
Acitretin—RBP1—Signaling Pathways—MMP9—systemic scleroderma	7.62e-06	0.00135	CbGpPWpGaD
Acitretin—RXRA—Developmental Biology—MMP9—systemic scleroderma	6.93e-06	0.00123	CbGpPWpGaD
Acitretin—RBP1—Signaling Pathways—TGFB1—systemic scleroderma	6.28e-06	0.00111	CbGpPWpGaD
Acitretin—RXRA—Developmental Biology—TGFB1—systemic scleroderma	5.71e-06	0.00101	CbGpPWpGaD
Acitretin—ALB—Hemostasis—MMP1—systemic scleroderma	5.33e-06	0.000946	CbGpPWpGaD
Acitretin—ALB—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	4.96e-06	0.000879	CbGpPWpGaD
Acitretin—ALB—Metabolism—HSPG2—systemic scleroderma	4.75e-06	0.000843	CbGpPWpGaD
Acitretin—ALB—Hemostasis—NOS3—systemic scleroderma	3.87e-06	0.000686	CbGpPWpGaD
Acitretin—ALB—Metabolism—CTGF—systemic scleroderma	3.6e-06	0.000639	CbGpPWpGaD
Acitretin—RXRA—Metabolism—NOS3—systemic scleroderma	3.44e-06	0.000609	CbGpPWpGaD
Acitretin—ALB—Hemostasis—TGFB1—systemic scleroderma	2.56e-06	0.000453	CbGpPWpGaD
Acitretin—ALB—Metabolism—NOS3—systemic scleroderma	1.57e-06	0.000278	CbGpPWpGaD
